Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Resistant Differentiated Thyroid Cancers: A Phase II Study

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) »